Longitudinal proneuroactive and neuroactive steroid profiles in medication-free women with, without and at-risk for perinatal depression: A liquid chromatography-tandem mass spectrometry analysis

  title={Longitudinal proneuroactive and neuroactive steroid profiles in medication-free women with, without and at-risk for perinatal depression: A liquid chromatography-tandem mass spectrometry analysis},
  author={Kristina M. Deligiannidis and Aimee R. Kroll-Desrosiers and Yanglan Tan and M. L. Dubuke and Scott A. Shaffer},

Figures and Tables from this paper

The adrenal steroid profile in adolescent depression: a valuable bio-readout?
The corticosterone to deoxycorticosterone ratio may prospectively qualify to contribute to precision medicine in psychiatry by identifying those patients who might benefit from antiglucocorticoid treatment or those at risk for recurrence when adrenal dysfunction has not resolved.
Allopregnanolone and depression and anxiety symptoms across the peripartum: an exploratory study
The exploratory findings indicate that the relationship between ALLO and mood and anxiety symptoms may change across the peripartum, and higher ALLO levels at W6 were associated with higher depression and anxiety scores.
Neuroactive steroids and depression in early pregnancy
Allopregnanolone Concentrations in Breast Milk and Plasma from Healthy Volunteers Receiving Brexanolone Injection, With Population Pharmacokinetic Modeling of Potential Relative Infant Dose
The rapid elimination of allopregnanolone from plasma and breast milk, and low RID, suggests the appropriateness of brexanolone weight-based dosing and supports other PK-related labeling recommendations.
Advances in pharmacotherapy for postpartum depression: a structured review of standard-of-care antidepressants and novel neuroactive steroid antidepressants
Postpartum depression is one of the most common morbidities of childbearing, yet it is underdiagnosed and undertreated with negative consequences for mother and offspring. Despite the widespread use
Effect of Zuranolone vs Placebo in Postpartum Depression
This randomized clinical trial assesses the efficacy and safety of zuranolone, a neuroactive steroid γ-aminobutyric acid receptor–positive allosteric modulator, in individuals with postpartum


Peripartum neuroactive steroid and γ-aminobutyric acid profiles in women at-risk for postpartum depression
Blunted neuroactive steroid and HPA axis responses to stress are associated with reduced sleep quality and negative affect in pregnancy: a pilot study
These data suggest that cortisol, progesterone, and ALLO + pregnanolone levels in the second trimester of pregnancy are inversely related to negative emotional symptoms, and the negative impact of acute stress challenge appears to exert its effects by reducing these steroids to further promote negative emotional responses.
Low Serum Allopregnanolone Is Associated with Symptoms of Depression in Late Pregnancy
High allopregnanolone serum concentrations may protect against depressed mood during pregnancy, and self-rated anxiety, however, was not associated with allopRegnanolones serum concentrations during pregnancy.
The EPDS-Lifetime: assessment of lifetime prevalence and risk factors for perinatal depression in a large cohort of depressed women
The EPDS-Lifetime shows promise as a tool for assessing lifetime histories of PND in clinical and research settings and found that two in five parous women with a history of MDD had lifetime PND and that the PND episodes were more severe than MDD occurring outside of the perinatal period.
Adverse life events, psychiatric history, and biological predictors of postpartum depression in an ethnically diverse sample of postpartum women
Psychiatric history and multiple exposures to adverse life events were significant predictors of PPD in a population of minority and low-income women, and genetic ancestry does not appear predictive.
5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder
Stabilization of allopregnanolone levels from the follicular to the luteal phase of the menstrual cycle by blocking the conversion of progesterone to its 5α-reduced neurosteroid metabolite mitigates symptoms in PMDD provides preliminary support for the pathophysiologic relevance of neurosteroids in this condition.